Qlife enters fully funded feasibility agreement with global pharma company for Egoo Health biomarker application
Summary
Qlife has signed a fully funded feasibility agreement with an undisclosed global pharmaceutical company. The partner will evaluate a specific biomarker on the Egoo Health platform for a therapeutic application. The study is the first step toward a possible long-term collaboration that could include dedicated R&D, regulatory work, and future system supply. The announcement highlights Qlife’s partner-led model and its focus on co-development programs with clear commercial potential.
Funding
Amount
None
Total raised
Date
June 1, 2026
Announcement date
Investors
-
Lead investors
Company
qlifeholding.com
Funded company
Classifications
industries
Financial Planning
applications
Financial Reporting
AskAI Classifications
Labels
No AI classifications detected